Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4630879 Target Snapshot

Hepatitis A virus cellular receptor 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
74Compounds
11Assays
0Approved Drugs
81.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Hepatitis A virus cellular receptor 2 shows late clinical disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q8TDQ0. Start with neoplasm, then reuse UniProt Q8TDQ0 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt Q8TDQ0 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs
Open source guide
Disease program
neoplasm

Hepatitis A virus cellular receptor 2 shows late clinical disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries late clinical support. Linked drugs include COBOLIMAB, LOMVASTOMIG, SABATOLIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Hepatitis A virus cellular receptor 2 as ChEMBL target CHEMBL4630879, mapped to UniProt Q8TDQ0. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Hepatitis A virus cellular receptor 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4630879
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q8TDQ0
Hepatitis A virus cellular receptor 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Hepatitis A virus cellular receptor 2 is the right protein anchor across sources, using UniProt Q8TDQ0 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as late clinical support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameHepatitis A virus cellular receptor 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ8TDQ0
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHepatitis A virus cellular receptor 2
UniProt AccessionQ8TDQ0
Component TypeProtein
Sequence Length301 aa

Hepatitis A virus cellular receptor 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Hepatitis A virus cellular receptor 2, mapped to UniProt Q8TDQ0. Sequence length is 301 aa.

Mapped IDQ8TDQ0
Review nameHepatitis A virus cellular receptor 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Hepatitis A virus cellular receptor 2 shows late clinical disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
neoplasm
3 linked drugs · 3 direct · 3 efficacy
Linked drugCOBOLIMAB
Linked drugLOMVASTOMIG
Linked drugSABATOLIMAB
Late clinical Phase III
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugSABATOLIMAB
Late clinical Phase III
myelodysplastic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugSABATOLIMAB
Clinical signal Phase II
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugSABATOLIMAB
Clinical signal Phase II
cervical cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugCOBOLIMAB
Clinical signal Phase II
cervical carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCOBOLIMAB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries late clinical support. Linked drugs include COBOLIMAB, LOMVASTOMIG, SABATOLIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC502.0
KI21.0
KD58.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5431861 9.24 Kd 0.58 Preclinical
CHEMBL4863322 7.16 Ki 70.0 Preclinical
CHEMBL4857707 6.96 Ki 110.0 Preclinical
CHEMBL4863017 6.81 Ki 156.0 Preclinical
CHEMBL5571782 6.8 Kd 160.0 Preclinical
CHEMBL4862554 6.79 Ki 164.0 Preclinical
CHEMBL4873816 6.69 Ki 204.0 Preclinical
CHEMBL4873902 6.6 Kd 250.0 Preclinical
CHEMBL5575871 6.57 Kd 270.0 Preclinical
CHEMBL4846481 6.54 Ki 287.0 Preclinical
Distribution

pChEMBL Value Distribution

9
5.0
18
5.5
10
6.0
9
6.5
1
7.0
0
7.5
0
8.0
0
8.5
1
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

11
Total Assays
71
Tested Compounds
1
Assay Types
Binding — 11 assays, 71 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 6 32 5.5
assay format 3 39 5.0
single protein format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine